1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Melinta Therapeutics, Inc - Product Pipeline Review - 2016

Melinta Therapeutics, Inc - Product Pipeline Review - 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 50 pages

Melinta Therapeutics, Inc - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Melinta Therapeutics, Inc - Product Pipeline Review - 2016’, provides an overview of the Melinta Therapeutics, Inc’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Melinta Therapeutics, Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Melinta Therapeutics, Inc
- The report provides overview of Melinta Therapeutics, Inc including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Melinta Therapeutics, Inc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Melinta Therapeutics, Inc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Melinta Therapeutics, Inc’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Melinta Therapeutics, Inc
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Melinta Therapeutics, Inc’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

Melinta Therapeutics, Inc - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Melinta Therapeutics, Inc Snapshot 5
Melinta Therapeutics, Inc Overview 5
Key Information 5
Key Facts 5
Melinta Therapeutics, Inc - Research and Development Overview 6
Key Therapeutic Areas 6
Melinta Therapeutics, Inc - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Melinta Therapeutics, Inc - Pipeline Products Glance 11
Melinta Therapeutics, Inc - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Melinta Therapeutics, Inc - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Melinta Therapeutics, Inc - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Melinta Therapeutics, Inc - Drug Profiles 15
delafloxacin 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
radezolid 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
RX-02 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
RX-04 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
RX-05 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
RXP-792 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
RXP-873 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
RXP-763 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
RXP-766 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
RXP-770 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
RXP-793 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
RXP-808 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Melinta Therapeutics, Inc - Pipeline Analysis 34
Melinta Therapeutics, Inc - Pipeline Products by Target 34
Melinta Therapeutics, Inc - Pipeline Products by Route of Administration 35
Melinta Therapeutics, Inc - Pipeline Products by Molecule Type 36
Melinta Therapeutics, Inc - Pipeline Products by Mechanism of Action 37
Melinta Therapeutics, Inc - Recent Pipeline Updates 38
Melinta Therapeutics, Inc - Dormant Projects 46
Melinta Therapeutics, Inc - Company Statement 47
Melinta Therapeutics, Inc - Locations And Subsidiaries 48
Head Office 48
Other Locations and Subsidiaries 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables
Melinta Therapeutics, Inc, Key Information 5
Melinta Therapeutics, Inc, Key Facts 5
Melinta Therapeutics, Inc - Pipeline by Indication, 2016 7
Melinta Therapeutics, Inc - Pipeline by Stage of Development, 2016 9
Melinta Therapeutics, Inc - Monotherapy Products in Pipeline, 2016 10
Melinta Therapeutics, Inc - Phase III, 2016 11
Melinta Therapeutics, Inc - Phase II, 2016 12
Melinta Therapeutics, Inc - Preclinical, 2016 13
Melinta Therapeutics, Inc - Discovery, 2016 14
Melinta Therapeutics, Inc - Pipeline by Target, 2016 34
Melinta Therapeutics, Inc - Pipeline by Route of Administration, 2016 35
Melinta Therapeutics, Inc - Pipeline by Molecule Type, 2016 36
Melinta Therapeutics, Inc - Pipeline Products by Mechanism of Action, 2016 37
Melinta Therapeutics, Inc - Recent Pipeline Updates, 2016 38
Melinta Therapeutics, Inc - Dormant Developmental Projects,2016 46
Melinta Therapeutics, Inc, Other Locations 48

List of Figures
Melinta Therapeutics, Inc - Pipeline by Top 10 Indication, 2016 7
Melinta Therapeutics, Inc - Pipeline by Stage of Development, 2016 9
Melinta Therapeutics, Inc - Monotherapy Products in Pipeline, 2016 10
Melinta Therapeutics, Inc - Pipeline by Target, 2016 34
Melinta Therapeutics, Inc - Pipeline by Route of Administration, 2016 35
Melinta Therapeutics, Inc - Pipeline by Molecule Type, 2016 36
Melinta Therapeutics, Inc - Pipeline Products by Mechanism of Action, 2016 37

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.